2. Academic Validation
  3. Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity

  • Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038.
Adam K Charnley 1,  Máire A Convery 2,  Ami Lakdawala Shah 3,  Emma Jones 4,  Philip Hardwicke 4,  Angela Bridges 4,  Michael Ouellette 3,  Rachel Totoritis 3,  Benjamin Schwartz 3,  Bryan W King 3,  David D Wisnoski 3,  James Kang 5,  Patrick M Eidam 5,  Bartholomew J Votta 5,  Peter J Gough 5,  Robert W Marquis 5,  John Bertin 5,  Linda Casillas 5
Affiliations

Affiliations

  • 1 Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapy Area, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426, USA. Electronic address: adam.k.charnley@gsk.com.
  • 2 Platform Technology & Science, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK. Electronic address: maire.a.convery@gsk.com.
  • 3 Platform Technology & Science, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
  • 4 Platform Technology & Science, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
  • 5 Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapy Area, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
PMID: 26455654 DOI: 10.1016/j.bmc.2015.09.038
Abstract

Receptor interacting protein 2 (RIP2) is an intracellular kinase and key signaling partner for the Pattern Recognition Receptors NOD1 and NOD2 (nucleotide-binding oligomerization domain-containing proteins 1 and 2). As such, RIP2 represents an attractive target to probe the role of these pathways in disease. In an effort to design potent and selective inhibitors of RIP2 we established a crystallographic system and determined the structure of the RIP2 kinase domain in an apo form and also in complex with multiple inhibitors including AMP-PCP (β,γ-Methyleneadenosine 5'-triphosphate, a non-hydrolysable adenosine triphosphate mimic) and structurally diverse ATP competitive chemotypes identified via a high-throughput screening campaign. These structures represent the first set of diverse RIP2-inhibitor co-crystal structures and demonstrate that the protein possesses the ability to adopt multiple DFG-in as well as DFG-out and C-helix out conformations. These structures reveal key protein-inhibitor structural insights and serve as the foundation for establishing a robust structure-based drug design effort to identify both potent and highly selective inhibitors of RIP2 kinase.

Keywords

CARD3; CARDIAK; Inhibitor selectivity; Kinase inhibitor; Kinase structure; RICK; RIP2; RIPK2; Structure-based drug design; X-ray cocrystal structure.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z